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Abstract: In the last years there has been increasing evidence suggesting that the treatment 
of cardiovascular risk factors must be done on a global rather than on a separate approach, 
because they have additive effects and share common pathways leading to atherothrombosis. 
Of special interest is the relationship between hypertension and dyslipidemia. An excessive 
activity of the renin-angiotensin system (RAS), that plays an important role in hypertension, 
contributes to endothelial dysfunction, vascular inﬂ  ammation and thrombosis. Dyslipidemia 
induces the same effects through similar mechanisms. In fact, combined therapy with statins 
and RAS modulators shows synergic beneﬁ  cial effects in the treatment of atherosclerosis. Then, 
in the future, the traditional hypertension and dyslipidemia units should probably evolve into 
global cardiovascular risk management Units. Also, polypills combining antihypertensive and 
lipid-lowering drugs will make easier the treatment of these conditions. These changes would 
provide us the necessary tools to treat our patients in accordance with the current strategies of 
cardiovascular therapy and prevention.
Keywords: Angiotensin, atherosclerosis, endothelium, hypercholesterolemia, hypertension, 
inﬂ  ammation
Many years ago, the Framingham study and other studies began to identify a number 
of different risk factors as potential causes of atherothrombotic events (Kannel et al 
1961; McGill 1996). Treating these risk factors emerged then as a capital task in the 
ﬁ  ght against cardiovascular disease. However, this approach has evolved notoriously 
in the last years. In the initial era, cardiovascular risk factors (CRF) were assessed and 
treated separately, but later, the avalaible information has shown us that this work has 
to be done based on a global approach. Clinical studies have demonstrated that CRF 
act in a synergistic way. In addition, we have learned from pathophysiological studies 
that there are mechanistic links between the pathways through which different CRF 
cause atherothrombosis. In this regard, of special interest is the relationship between 
the pathophysiology of hypertension and dyslipidemia.We will focus on the clinical 
and pathophysiological data relating to the development of these two factors, to sup-
port the concept of a global management of the patient with CRF.
Combined antihypertensive and lipid lowering 
therapies in the clinical practice
A large number of clinical trials has demonstrated that treatment of either hypercho-
lesterolemia or hypertension leads to a reduction in the incidence of cardiovascular Vascular Health and Risk Management 2007:3(4) 522
Tuñón et al
events. Also, statins and angiotensin converting enzyme 
(ACE) inhibitors demonstrated an additive effect reducing the 
incidence of cardiovascular events (Yusuf et al 2000; Heart 
Protection Study Collaborative Group 2002).
The Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) studies have shed new light into this mat-
ter. The ASCOT-BPLA (Blood Pressure Lowering 
Arm) analyzed 19,257 patients with hypertension and 
at least three other cardiovascular risk factors, which 
were randomized to therapy with amlodipine, adding 
perindopril when necessary, or to atenolol, using ben-
droﬂ  umethiazide as a second drug (Dahlof et al 2005). 
By the end of the trial, 78% of patients were taking the 
second antihypertensive drug, and the amlodipine/per-
indopril regimen was superior to atenolol in terms of 
all-cause mortality, stroke, total cardiovascular events 
and procedures and new-onset diabetes.
When several variables of the ASCOT-BPLA were 
analyzed, blood pressure reduction was not the only 
contributor to the amlodipine/perindopril decrease in 
cardiovascular events (Poulter et al 2005). Interestingly, 
although blood pressure was the most important vari-
able associated with the incidence of stroke, differences 
in HDL cholesterol were more important for coronary 
events. Furthermore, full adjustment for these variables 
as well as for bodyweight, and glucose, triglycerides, 
creatinine and potassium serum levels explained only 
50% and 40% of the differences in coronary and stroke 
events, respectively, leaving the remaining percent-
ages to be potentially explained by other variables not 
considered in this analysis. These data suggest that 
blood pressure reduction is not the only mediator in 
the beneﬁ  cial effect of antihypertensive drugs. Accord-
ingly, several vasculoprotective mechanisms have been 
demonstrated for anti-hypertensive drugs, the most 
important of which have been described for those that 
modulate the renin-angiotensin system (RAS). The 
same holds true for statins, which have been claimed 
to exert a part of their beneﬁ  cial actions by cholesterol-
independent mechanisms (Blanco-Colio et al 2003; 
Ray et al 2005).
The ASCOT-LLA (Lipid Lowering Arm), pub-
lished in 2003, showed data of further interest (Sever 
et al 2003). Ten thousand three-hundred ﬁ  ve patients 
from the ASCOT-BPLA study with total cholesterol 
concentrations of 6.5 mmol/L or less were randomized 
to atorvastatin 10 mg/d or placebo. Treatment with the 
statin reduced the incidence of non-fatal myocardial 
infarction or fatal coronary heart disease and that of 
stroke, cardiovascular and coronary events. Thus, using 
statins in patients with moderately increased or even 
normal cholesterol levels, but at risk of cardiovascular 
events because of accompanying hypertension and other 
CRF, improved their clinical evolution. Remarkably, 
in the ASCOT-BPLA, an optimal prevention of cardio-
vascular events was reached in patients randomized to 
atorvastatin and the amlodipine/perindopril treatment, 
with a reduction of 48% in the risk of fatal myocardial 
infarction and non-fatal coronary heart disease and 
44% in the incidence of stroke (http://www.broadshow.
com/ascot/press-material.php).
Dyslipidemia and hypertension 
share common pathways leading 
to atherothrombosis
Three ﬁ  ndings are of special interest in the above-mentioned 
data. First, a statin, a cholesterol-lowering drug, is beneﬁ  cial 
in the treatment of patients who are at risk of cardiovascular 
events because of the coexistence of several risk factors for 
atherothrombosis, even when their cholesterol levels are 
normal or only moderately elevated. Second, blood pres-
sure control and lipid lowering seem not to account for all 
the reduction achieved by antihypertensive and statin treat-
ments respectively. And, third, the combination of a statin 
and an effective antihypertensive regimen leads to the best 
prevention results.
These facts suggest that the pathophysiologic pathways 
that link hypertension and dyslipidemia to atherothrombosis 
may share common mechanisms, and this may be similar for 
other cardiovascular risk factors. This idea is supported by 
clinical data showing that statins may diminish blood pres-
sure levels (Glorioso et al 1999). However, most evidence 
supporting this possibility comes from basic research. In this 
setting, the enhanced activity of the RAS, which plays an 
important role in hypertension, can activate similar mecha-
nisms to dyslipidemia in endothelial dysfunction, inﬂ  amma-
tion and thrombosis.
Endothelial dysfunction in the crossroad 
between hypertension and dyslipidemia
All major atherothrombotic risk factors induce endo-
thelial dysfunction. The key feature in this disorder is a 
reduced availability of nitric oxide (NO) due to both a 
decrease in its synthesis and to an enhanced degradation. 
Hypercholesterolemia plays an important role in this setting, Vascular Health and Risk Management 2007:3(4) 523
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as oxidized LDL diminishes the expression of endothelial 
NO synthase (eNOS) (Laufs et al 1998). Furthermore, in 
hypercholesterolemia there is an increase of asymmetric 
dimethylarginine levels, an eNOS endogenous inhibitor (Ito 
et al 1999). Angiotensin (Ang) II may also downregulate 
eNOS expression via protein-kinase C (Harrison et al 1995), 
thus leading to a decrease in NO production. In addition, 
both hypercholesterolemia and Ang II can participate in NO 
degradation. Oxidized LDL contributes to oxidative stress, 
where superoxide anion is generated by endothelial oxidase 
enzymes. Superoxide reacts with NO yielding peroxynitrite 
(ONOO-), a compound which, in high amount, works as a 
strong oxidant and is toxic to proteins (Ischiropoulos et al 
1995). On the other hand, Ang II is a powerful oxidant agent 
that increases superoxide anion production through NADH/
NADPH in vivo an in vitro via AT1 receptors (Rajagopalan 
et al 1996). Angiotensin II can generate reactive oxygen 
species (ROS), which activate different intracellular signal-
ing cascades, including mitogen-activated protein kinases 
(MAPK) and the transcription factor NF-κB (Hernández-
Presa et al 1997; Ushio-Fukai et al 1998). Statins are able to 
counterbalance the effect of oxidative stress, and decrease 
the NF-κB activity induced by superoxide anion (Ortego 
et al 1999).
In the setting of endothelial dysfunction, there is an 
increase in vascular permeability to LDL, which becomes 
oxidized in the arterial wall where the macrophages uptake 
them evolving into foam cells. These processes are promoted 
by AT1 receptor activation (Keidar et al 1997). In fact, the 
expression of the oxidized LDL receptor LOX is enhanced 
through AT1 activation (Morawietz et al 1999). Moreover, 
the expression of this receptor is induced by LDL in vascu-
lar smooth muscle cells, and is enhanced in experimental 
models of atherosclerosis (Nickenig et al 1997; Warnholtz 
et al 1999). In addition, ACE is present in greater amounts in 
atherosclerotic plaques (Diet et al 1996). Thus, lipid-lowering 
drugs are not the unique strategy to lessen these LDL-related 
biological processes. In agreement with these data, angioten-
sin receptor blockers (ARBs) have been shown to decrease 
atheroma formation (Warnholtz et al 1999).
According to all this evidence, multiple studies in the 
literature have demonstrated that both statins and RAS in-
hibitors improve the endothelial function in human beings 
(Mancini et al 1996; O’Driscoll et al 1997; Tuñón et al 2004; 
Ceriello et al 2005). Furthermore, there is an additive effect 
of hypertension and dyslipidemia. The infusion of Ang 
II in patients with hypercholesterolemia increases blood 
pressure and AT1 expression more than twice as compared 
with healthy subjects, and these responses are normalized 
by treatment with statins (Nickenig et al 1999). Finally, the 
combination of a statin and an ARB are superior to each 
drug alone in reducing the extent of atherosclerosis and the 
expression of LOX-1 and p38 MAPK in the apo-E knockout 
mice (Chen et al 2006). This fact reinforces the idea of the 
interplay between the atherothrombotic pathways of the RAS 
and hypercholesterolemia.
Common pathways to inﬂ  ammation 
for Ang II and dyslipidemia
Another important feature in the pathophysiology of ath-
erothrombosis is inﬂ  ammatory cell recruitment into the 
vascular wall. This phenomenom is due to the expression 
of adhesion and chemoattractant molecules by the endothe-
lium, which is regulated, among others, by the transcription 
factor NF-κB (Barnes et al 1997). This transcription factor 
plays a key role in the atherothrombotic process, since it also 
controls the expression of many other proinﬂ  ammatory and 
prothrombotic proteins, including that of tissue factor, the 
trigger of thrombosis in the atheroma plaque. The activation 
of NF-κB is enhanced, among other stimuli, by ROS and 
oxLDL, and inhibited by HDL (Barnes et al 1997; Xu et al 
1999; Robbesyn et al 2003). In this regard, we have shown 
that statins decrease NF-κB activity in vitro and in a rabbit 
model of atherosclerosis (Bustos et al 1998; Ortego et al 
1999). However, we have also demonstrated that Ang II is 
able to induce NF-κB activity in cultured monocytic and 
vascular smooth muscle cells (Hernández-Presa et al 1997). 
In this effect, Ang II-induced ROS generation may play an 
important role, as it was inhibited by pyrrolidinedithiocarba-
mate (Ortego et al 1999). In fact, ARB treatment diminishes 
free radical generation and NF-κB binding in mononuclear 
cells of healthy subjects (Dandona et al 2004).
In addition, Ang II induces leukocyte-endothelial cell 
interactions and upregulates the expression of several 
adhesion molecules and chemoattractant cytokines, includ-
ing MCP-1 (monocyte chemoattractant protein-1), IL-6 
(interleukin-6), and IL-8, mainly through AT1 receptors 
(Hernandez-Presa et al 1997; Schieffer et al 2000; Ito et al 
2002; Riaz et al 2004). In addition, RAS inhibitors decrease 
inﬂ  ammation in human beings and in experimental models 
of atherosclerosis (Hernández-Presa 1997, 1998; Cipollone 
et al 2004; Fliser et al 2004). For instance, the ARB irbe-
sartan reduces macrophage inﬁ  ltration, and the expression 
of the proinﬂ  ammatory enzyme cyclooxygenase-2 (COX-2) 
and metalloproteinases in human carotid plaques (Cipollone 
et al 2004). Also, olmesartan has demonstrated recently to Vascular Health and Risk Management 2007:3(4) 524
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diminish plasma levels of C reactive protein, TNF-α, IL-1 
and MCP-1 in patients with arterial hypertension and micro-
inﬂ  ammation (Fliser et al 2004).
With regard to statins, there is a huge amount of infor-
mation showing that they may downregulate the NF-κB 
pathway, decreasing the expression of adhesion molecules, 
chemoattractant cytokines, that of the proinflammatory 
enzyme COX-2 and plasma levels of several inﬂ  ammatory 
markers (Bustos et al 1998; Hernández-Presa et al 1998; 
Ortego et al 1999; Blanco-Colio et al 2003). In this regard, 
we have demonstrated that atorvastatin decreases NF-κB 
activity, MCP-1 expression and macrophage inﬁ  ltration in 
human atherosclerotic plaques in only one month of treatment 
(Martín-Ventura et al 2005). Of interest, the expression of 
metalloproteinases is enhanced by Ang II in smooth muscle 
cells and reduced by statins (Luan et al 2003; Luchtefeld 
et al 2005). Furthermore, statins are able to inhibit the Ang 
II-induced expression of MCP-1 and IL-8 in vascular smooth 
muscle cells (Ortego et al 1999; Ito et al 2002), conﬁ  rming 
the interaction between the inﬂ  ammatory pathways triggered 
by dyslipidemia and the RAS. Finally, the combination of 
atorvastatin and irbesartan reduced C-reactive protein and 
IL-6 levels more effectively than each of two drugs alone in 
diabetic patients (Ceriello et al 2005).
There are other crosslinks between RAS and statins in 
inﬂ  ammation. Vascular permeability is augmented by Ang 
II via AT1 receptors, while it is decreased by statins (Bonetti 
et al 2002; Victorino et al 2002). Ang II and dyslipidemia 
share also their effects on ﬁ  brosis, the part of the inﬂ  am-
matory process that repairs the damaged tissue, but that in 
atherosclerosis also results in plaque growth. In this sense, 
the expression of PDGF (platelet-derived growth factor), 
TGF-β1 (transforming growth factor-β1) and CTGF (connec-
tive tissue growth factor), that mediate the growth-promot-
ing effect of Ang II, is reduced not only by ARBs and ACE 
inhibitors, but also by statins (Grandaliano et al 1993; Wong 
et al 1997; Kim et al 2000; Iwanciw et al 2003; Rupérez et al 
2003). Moreover, these drugs are able to decrease Ang II-
induced expression of CTGF (Iwanciw et al 2003).
Lipids, RAS and thrombosis
Thrombosis is a critical component of the atheroscle-
rotic disorder, and leads to acute coronary syndromes 
and ischemic stroke. It begins with platelet adhesion 
and aggregation, followed by activation of the coagu-
lation cascade. Tissue factor activation is the ﬁ  rst step 
of the cascade coagulation in vascular thrombosis, and 
this factor is present in the lipid core component of the 
atherosclerotic plaques (Toschi et al 1997). Platelets 
express AT1 receptors, and ACE inhibitors and ARBs 
have been demonstrated to inhibit platelet aggregration 
(James et al 1988; Crabos et al 1993; Schieffer et al 
2004). Also, losartan works as a competitive antagonist 
of thromboxane A2, a compound derived from COX-
1 activity which induces platelet aggregation (Corriu 
et al 1995). Statins also interfere with these pathways, 
as they diminish platelet aggregation, thromboxane A2 
synthesis and thrombin-induced tissue factor expression 
in endothelial cells (Davi et al 1992; Notarbartolo et al 
1995; Eto et al 2002). Moreover, Ang II induces tissue 
factor expression in human monocytes via the protein 
kinase C pathway, and ARBs decrease tissue factor 
activity in hypertensive patients (Koh et al 2004; He 
et al 2006). Also, RAS is involved in the regulation of 
the endogenous ﬁ  brinolytic system. Ang II induces the 
expression of the inhibitor of spontaneous thrombolysis 
PAI-1 (plasminogen activator inhibitor type 1), and 
RAS inhibitors decrease PAI-1 plasma levels, which 
are enhanced following a myocardial infarction (Wright 
et al 1994; Koh et al 2004). Moreover, ACE inhibitors 
block bradykinin degradation, and this peptide induces 
the expression of t-PA (tissue plasminogen activator) 
(Vaughan et al 1995). Similarly, statins increase the 
synthesis of t-PA and decrease PAI-1 (Essig et al 1998; 
Bourcier et al 2000). Very recently, we have observed 
that intensive treatment with atorvastatin after an 
acute coronary syndrome enhances the expression of 
annexin II, a receptor for tissue plasminogen activator 
and plasminogen, in circulating monocytes (Tuñón 
et al 2007). In conclusion, Ang II and dyslipidemia 
also act through common mechanisms to promote 
thrombus formation, which is ultimately responsible for 
acute ischemic events in atherothrombosis. Combining 
adequately RAS modulators with statins may reduce 
the probabilities of developing cardiovascular events 
by interfering with these actions.
Clinical implications
Several pathways of the essential biological processes in 
atherothrombosis are shared by dyslipidemia and Ang II, 
and these mechanisms are targets for RAS modulators 
and statins. Then, the isolated approach to the treatment 
of separated risk factors for atherothrombosis seems to be 
over, since evidence from basic and clinical research clearly 
indicates that the pathways by which multiple risk factors 
lead to this disorder are strongly interrelated. In fact, cur-Vascular Health and Risk Management 2007:3(4) 525
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rent practice guidelines for the management of hypertension 
and dyslipidemia take into account the existence of other 
risk factors to advice the intensity of antihypertensive and 
cholesterol-lowering therapy. Moreover, polypill combi-
nations of antihypertensive and lipid-lowering drugs are 
already available in one tablet, such as amlodipine and 
atorvastatin (CADUET), and others, such as ARB and 
statins, will be probably coming soon. It follows that the 
next step for this approach should be the evolution of the 
traditional hypertension and dyslipidemia Units into car-
diovascular risk management departments. These changes 
would provide the necessary tools to treat our patients in 
accordance with the current strategies of cardiovascular 
therapy and prevention.
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